KLRC1 and neoplasm: However, in these in vivo experiments, we primarily focused on the therapeutic effects of MS-275 in combination with NK cells and NKG2A blockade, without evaluating the NK cell status by collecting tumor samples through flow cytometry or immunohistochemistry several days after administering NK cells.